Oslo, 1 September 2022: Reference is made to the stock exchange release on 11
January 2021, with the announcement of the agreement between Aker BioMarine and
biotech entrepreneur Dr. Michael Davidson for the development of pharmaceutical
therapies for brain and eye diseases based on Aker BioMarine's product Lysoveta.

As a result of this collaboration, Aker BioMarine has signed an agreement with
Trofi Nutritional Inc. ("Trofi") with the aim to develop medical foods products
based on Lysoveta, targeting Alzheimer's disease, male infertility and
gestational diabetes, in addition to pre-natal supplements in the US.

"These diseases have a severe impact on the lives for a large proportion of the
population globally. The collaboration with Trofi is an important milestone in
commercializing Lysoveta and we will continue to build the body of scientific
evidence for Lysoveta's beneficial effects across life stages.", said Matts
Johansen, CEO in Aker BioMarine.

According to the Center for Disease Control and Prevention (CDC), there is an
increase in these diseases in the US population. Both increased life expectancy
and lifestyle-related risk factors for these diseases are seen as contributions
to this increase.  There are limited available therapeutical options in today's
healthcare system.

Under the agreement, Aker BioMarine will license, with associated royalties on
sales, relevant intellectual property rights and supply Lysoveta to Trofi, who
will invest in clinical trials with the aim to develop and commercialize certain
medical foods within the fields. Launch of first medical food and dietary
supplement is planned for 2024.

About Trofi Nutritional Inc.
Trofi is an early-stage pioneer in next-generation nutritional solutions
designed to support a range of health needs from managing chronic conditions to
achieving wellness goals. 

The company was co-founded by Dr. Michael Davidson, Clinical Professor of
Medicine and Director of the Lipid Clinic at the University of Illinois,
together with Jonathan Jonas, CEO of JVC investment Partners. Trofi is headed by
CEO Barbara McCartney, an accomplished multi-country business leader in the
food, nutrition and wellness space. See also www.trofinutritionals.com.

About Lysoveta
Lysoveta features essential nutrients such as choline, EPA and DHA in the form
of Lysophosphatidylcholine (LPC). LPC is a molecule with the unique ability to
be transported across the blood brain barrier containing important nutrients for
the brain functioning. 

With the new Lysoveta product area, Aker BioMarine targets to raise market
awareness, both through further scientific and commercial collaborations, as
well as investing in a broad pre-clinical and clinical pipeline. The company is
currently scaling up production of a Lysoveta dietary supplement line at its
manufacturing plant in Houston, USA, and aims to introduce first product in the
US market during 2023.


For further information, please contact:
Carl Christian Bachke, Investor Relations
Mobile: +47 909 808 48
Email: carl.bachke@akerbiomarine.com 


About Aker BioMarine ASA
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. The
company's focus on sustainability inspired the launch of AION that assists
companies to recycle and reuse waste. Aker BioMarine is listed on Oslo Stock
Exchange (AKBM). See also www.akerbiomarine.com.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange